Latest Content

RSV vaccines and nirsevimab are linked to reduced infant hospitalizations, though seasonal spikes and data limitations remain concerns.

Radioligand therapy expands patient access in community oncology, pairing precision imaging with safe local delivery so patients stay close to home. This commentary will appear in the May issue of Evidence-Based Oncology.

MASH cirrhosis carries high risks of death, decompensation, and liver cancer—especially with type 2 diabetes—while predictive tools remain limited.

Psoriasis carries significant psychological and social burden, but adding mind-body approaches like CBT to treatment may improve mental health and outcomes.

The COA Community Oncology Conference will tackle AI, the rollout of bispecifics and CAR T in the community setting, plus reimbursement, radiation oncology, and patient access strategies.

Deuruxolitinib shows consistent efficacy across subgroups and drives early hair regrowth in severe alopecia areata, with gains seen by 8 weeks.

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

Chimeric antigen receptor-based immunotherapies show promise when directed at viral targets, but data are limited.

The benefits of exercise are particularly notable for patients who are dependent upon dialysis, a new review suggests.